Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Roquefort Investments PLC ( (GB:ROQ) ) just unveiled an update.
Roquefort Therapeutics PLC announced the signing of a term sheet for the proposed sale of its subsidiary, Lyramid Pty Ltd, to Pleiades Pharma Limited for a minimum of US$10 million. This transaction is part of Roquefort’s strategy to acquire, develop, and realize value through licensing and trade-sale transactions, allowing them to capitalize on valuation arbitrage and retain potential upside in the Midkine portfolio. Post-transaction, Roquefort will hold a significant equity position in Pleiades, which is developing a novel clinical and pre-clinical medicines portfolio.
More about Roquefort Investments PLC
Roquefort Therapeutics PLC is a Main Market listed biotech company focused on developing first-in-class medicines within the high-value and high-growth immunology and oncology sectors. The company has a portfolio of five novel pre-clinical anti-cancer medicines, which include Midkine antibodies, RNA therapeutics, mRNA therapeutics, STAT-6 siRNA therapeutics, and MK cell therapy, all aimed at partnering with big pharma.
Average Trading Volume: 1,403,504
Technical Sentiment Consensus Rating: Hold
Current Market Cap: £5.5M
Find detailed analytics on ROQ stock on TipRanks’ Stock Analysis page.
